Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's neratinib (NERLYNX) therapy and dose escalation are included in the updated NCCN Guidelines for the treatment of breast cancer .

Click to view original post